{"id":9152,"date":"2023-03-16T06:40:49","date_gmt":"2023-03-16T10:40:49","guid":{"rendered":"https:\/\/dbv-technologies.com\/notre-science\/publications-scientifiques-et-presentations\/"},"modified":"2025-09-16T14:09:12","modified_gmt":"2025-09-16T18:09:12","slug":"publications-scientifiques-et-presentations","status":"publish","type":"page","link":"https:\/\/dbv-technologies.com\/fr\/notre-science\/publications-scientifiques-et-presentations\/","title":{"rendered":"Publications scientifiques et pr\u00e9sentations"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"9152\" class=\"elementor elementor-9152 elementor-8351\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-94b42d9 page-hero e-flex e-con-boxed e-con e-parent\" data-id=\"94b42d9\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2771618 page-title elementor-widget elementor-widget-heading\" data-id=\"2771618\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Publications scientifiques et pr\u00e9sentations<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-c9a53ef e-flex e-con-boxed e-con e-parent\" data-id=\"c9a53ef\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ad024cf elementor-widget elementor-widget-text-editor\" data-id=\"ad024cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Ces publications scientifiques et pr\u00e9sentations sont propos\u00e9es \u00e0 des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de d\u00e9veloppement, et qui ne sont approuv\u00e9s pour commercialisation par aucune autorit\u00e9 r\u00e8glementaire ou de sant\u00e9 dans aucun pays du monde.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-95fb77b e-flex e-con-boxed e-con e-child\" data-id=\"95fb77b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-33579db e-con-full e-flex e-con e-child\" data-id=\"33579db\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-475ffde elementor-widget elementor-widget-heading\" data-id=\"475ffde\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Publications importantes<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-81ee22a elementor-widget elementor-widget-shortcode\" data-id=\"81ee22a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\"><div class=\"search-filter-results\" id=\"search-filter-results-8469\">\t<div class='resources-container'>\n\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Scurlock AM, Fleischer DM, Toit GD, et al<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Children with Atopic Comorbidities<\/div>\n\t\t\t\t<div class=\"resource-source\">Ann Allergy Asthma Immunol. Published online April 7th 2025. PMID: 40204253. | <a href=\"https:\/\/www.annallergy.org\/article\/S1081-1206(25)00179-6\/fulltext\" target=\"_blank\" class=\"resource-link\">doi: 10.1016\/j.anai.2025.04.002.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Pongracic JA, Gagnon R, Sussman G, et al<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)<\/div>\n\t\t\t\t<div class=\"resource-source\">J Allergy Clin Immunol Pract. Published online February 27, 2025. PMID: 40023371. | <a href=\"https:\/\/www.jaci-inpractice.org\/article\/S2213-2198(25)00196-5\/pdf\" target=\"_blank\" class=\"resource-link\">doi: 10.1016\/j.jaip.2025.02.024. <\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Greenhawt M, Albright D, Anvari S, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE<\/div>\n\t\t\t\t<div class=\"resource-source\">J Allergy Clin Immunol Pract. Published online February 14, 2025. PMID: 39956162  | <a href=\"https:\/\/www.jaci-inpractice.org\/article\/S2213-2198(25)00166-7\/fulltext\" target=\"_blank\" class=\"resource-link\">doi:10.1016\/j.jaip.2025.02.004<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Petroni D, B\u00e9gin P, Bird JA, et al. <\/div>\t\n\t\t\t\t<div class=\"resource-title\">Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow&rsquo;s Milk Allergy: A Randomized Clinical Trial<\/div>\n\t\t\t\t<div class=\"resource-source\">JAMA Pediatr. 2024; 178(4): 345\u2013353. PMID: 38407859 | <a href=\"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2815455\" target=\"_blank\" class=\"resource-link\">doi: 10.1001\/jamapediatrics.2023.6630<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Dupont C, Burks AW, Fleischer DM, Bee KJ, Chainani S, Sampson HA<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy<\/div>\n\t\t\t\t<div class=\"resource-source\">Expert Rev Clin Immunol. Published online February 14, 2024. PMID: 38323337 | <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2024.2315221\" target=\"_blank\" class=\"resource-link\">doi:10.1080\/1744666X.2024.2315221<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Stukus DR, Gupta R, Mack D, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Epicutaneous immunotherapy with Viaskin\u2122 Peanut in toddlers: a plain language summary<\/div>\n\t\t\t\t<div class=\"resource-source\">Immunotherapy. 2024;16(1):5-13. PMID: 38112107 | <a href=\"https:\/\/www.futuremedicine.com\/doi\/10.2217\/imt-2023-0201\" target=\"_blank\" class=\"resource-link\">doi:10.2217\/imt-2023-0201<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Herv\u00e9 PL, Dioszeghy V, Matthews K, Bee KJ, Campbell DE, Sampson HA<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Recent advances in epicutaneous immunotherapy and potential applications in food allergy<\/div>\n\t\t\t\t<div class=\"resource-source\">Front Allergy. 2023;4:1290003. PMID: 37965375 | <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1290003\/full\" target=\"_blank\" class=\"resource-link\">doi:10.3389\/falgy.2023.1290003<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Matthew Greenhawt, M.D.,\u00a0Sayantani B. Sindher, M.D.,\u00a0Julie Wang, M.D.,\u00a0et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy<\/div>\n\t\t\t\t<div class=\"resource-source\">New England Journal of Medicine 2023; 388:1814-1815 | <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2212895\" target=\"_blank\" class=\"resource-link\">doi:10.1056\/NEJMe2301157<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Pongracic JA, Gagnon R, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results<\/div>\n\t\t\t\t<div class=\"resource-source\">J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. | <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219821012952?dgcid=rss_sd_all\" target=\"_blank\" class=\"resource-link\">doi:10.1016\/j.jaip.2021.11.017<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">B\u00e9gin P, Bird JA, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy<\/div>\n\t\t\t\t<div class=\"resource-source\">Allergy. 2021. Dec;76(12):3835-3838. | <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15083\" target=\"_blank\" class=\"resource-link\">doi: 10.1111\/all.15083.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Remington BC, Koppelman SJ, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance<\/div>\n\t\t\t\t<div class=\"resource-source\">Allergy. 2021. Oct;76(10):3223-3226. | <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.14973\" target=\"_blank\" class=\"resource-link\">doi: 10.1111\/all.14973.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Brown-Whitehorn TF, de Blay F, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy<\/div>\n\t\t\t\t<div class=\"resource-source\">The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. | <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219820308333?via%3Dihub\" target=\"_blank\" class=\"resource-link\">doi: 10.1016\/j.jaip.2020.08.017.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">DunnGalvin A, Fleischer DM, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies<\/div>\n\t\t\t\t<div class=\"resource-source\">The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. | <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S221321982030831X?via%3Dihub\" target=\"_blank\" class=\"resource-link\">doi: 10.1016\/j.jaip.2020.08.015.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Remington BC, Campbell DE, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results<\/div>\n\t\t\t\t<div class=\"resource-source\">Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. | <a href=\"https:\/\/www.annallergy.org\/article\/S1081-1206(20)31218-7\/fulltext\" target=\"_blank\" class=\"resource-link\">doi: 10.1016\/j.anai.2020.11.015.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Fleischer DM, Shreffler WG, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results<\/div>\n\t\t\t\t<div class=\"resource-source\">The Journal of Allergy and Clinical Immunology. 2020. | <a href=\"https:\/\/www.jacionline.org\/article\/S0091-6749(20)30957-X\/fulltext\" target=\"_blank\" class=\"resource-link\">doi:10.1016\/j.jaci.2020.06.028.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Greenhawt M, Kim EH, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Improvements in eliciting dose across baseline sensitivities following 12\u00a0months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years<\/div>\n\t\t\t\t<div class=\"resource-source\">The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. PMID: 32502548. | <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219820305262?via%3Dihub\" target=\"_blank\" class=\"resource-link\">doi:10.1016\/j.jaip.2020.05.030.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Fleischer DM, Chinthrajah S, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial<\/div>\n\t\t\t\t<div class=\"resource-source\">Allergy & Asthma Proceedings. 2020;41:1-10. PMID: 32539908. | <a href=\"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/00000005\/art00003\" target=\"_blank\" class=\"resource-link\">doi:10.2500\/aap.2020.41.200047.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Fleischer DM, Spergel JM, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy<\/div>\n\t\t\t\t<div class=\"resource-source\"> Allergy & Asthma Proceedings. 2020;41:278-284. PMID: 32517847. | <a href=\"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/00000004\/art00009\" target=\"_blank\" class=\"resource-link\">doi:10.2500\/aap.2020.41.200045<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Fleischer DM, Greenhawt M, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy<\/div>\n\t\t\t\t<div class=\"resource-source\">The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. PMID: 30794314. | <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2725896\" target=\"_blank\" class=\"resource-link\">doi:10.1001\/jama.2019.1113.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class='resource-item'>\n\t\t\t\t<div class=\"resource-author\">Sampson HA, Shreffler WG, et al.<\/div>\t\n\t\t\t\t<div class=\"resource-title\">Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity<\/div>\n\t\t\t\t<div class=\"resource-source\">A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. PMID: 29136445. | <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2662891\" target=\"_blank\" class=\"resource-link\">doi:10.1001\/jama.2017.16591.<\/a><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\t<!-- resource container close -->\n\t<div class=\"pagination\">\n\t\t<!--<div class=\"nav-previous\"><\/div>\n\t<div class=\"nav-next\"><\/div> -->\n\t\t<br \/>\t<\/div><!-- pagination close -->\n\t<\/div><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2df4e99 e-con-full callout-box e-flex e-con e-child\" data-id=\"2df4e99\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fb45ef5 elementor-widget elementor-widget-heading\" data-id=\"fb45ef5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\">Get the Quarterly Newsletter from DBV Technologies Medical Affairs &amp; Clinical Development<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-886f649 elementor-widget elementor-widget-button\" data-id=\"886f649\" data-element_type=\"widget\" data-e-type=\"widget\" aria-labe=\"SIgnup for Newsletter\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/dbv-technologies.com\/fr\/nous-contacter\/actualites-et-ressources\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">S\u2019inscrire<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-eff28f3 e-con-full e-flex e-con e-child\" data-id=\"eff28f3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-12bfee5 elementor-widget elementor-widget-heading\" data-id=\"12bfee5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Pr\u00e9sentations R\u00e9centes<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c5889c7 elementor-widget elementor-widget-text-editor\" data-id=\"c5889c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Ces r\u00e9sum\u00e9s ont \u00e9t\u00e9 approuv\u00e9s pour pr\u00e9sentation \u00e0 un congr\u00e8s m\u00e9dical et n\u2019ont pas \u00e9t\u00e9 soumis \u00e0 une revue compl\u00e8te par des pairs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-81599e0 elementor-widget elementor-widget-text-editor\" data-id=\"81599e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit, June 27-29, 2025:<\/h3><div><h4>Poster Presentation:<\/h4><ul><li>Efficacy and Safety of Long-Term Epicutaneous Immunotherapy in Peanut-Allergic Children in Multiple Phase 3 Clinical Trials &#8211; Green TD, Anvari S, Brown-Whitehorn T, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/09\/DBV2538292_CFAAR2025_PEOPLEEPOPEX_062325_V4_Final-1.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-df88e81 elementor-widget elementor-widget-text-editor\" data-id=\"df88e81\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Meeting, June 13-16, 2025:<\/h3><div><h4>Poster Presentations:<\/h4><ul><li>Real-World Protective Effects of Peanut Epicutaneous Immunotherapy in Allergic Toddlers &#8211; Lieberman JA, Arends N, Kim EH, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/06\/DBV2538292_APC-Part-2_EAACI2025_052325_V8_Final_For-Print.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><li>Phase 2 Study to Evaluate the Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic Tool for Non\u2013IgE-Mediated Cow\u2019s Milk Allergy in Children (APTITUDE) &#8211; Canani RB, Baker MG, Dhillon Y, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/06\/DBV2538292_APTITUDE_05222025_V4_Final.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-16e274b elementor-widget elementor-widget-text-editor\" data-id=\"16e274b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Eastern Allergy Conference, May 29-June 1, 2025:<\/h3><div><h4>Poster Presentations:<\/h4><ul><li>COMFORT Toddlers: Phase 3 Supplemental Safety Study of Epicutaneous Immunotherapy in 1- Through 3-Year-Old Peanut-Allergic Toddlers &#8211; Wang J, Anvari S, Greenhawt M, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/06\/DBV2538292_EAC2025_COMFORT-Toddlers_052725_V5_Final.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><li>Efficacy and Safety of Long-Term Epicutaneous Immunotherapy in Peanut-Allergic Children Aged 4 Through 7 Years in the Phase 3 PEOPLE Trial &#8211; Fleischer DM, Chinthrajah RS, Leonard S, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/06\/DBV2538292_EAC2025_PEOPLE-4-7_052725_V4_Final.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7717cbb elementor-widget elementor-widget-text-editor\" data-id=\"7717cbb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Western Society of Allergy, Asthma and Immunology (WSAAI) 2025 Annual Scientific Session, February 9-13, 2025:<\/h3><div><h4>Poster Presentation:<\/h4><ul><li style=\"list-style-type: none;\"><ul><li>VITESSE Phase 3 Study of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy in Children &#8211; Fleischer DM, Wang J, Leflein J, et al [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/07\/DBV2536046_VITESSE_WSAAI_020325_V3_For-Print.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><\/ul><\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b6b79dc elementor-widget elementor-widget-text-editor\" data-id=\"b6b79dc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>Oral abstract for American Academy of Allergy, Asthma &amp; Immunology (AAAAI)\/ World Allergy Organization (WAO) 2025 Joint Congress, February 28-March 3, 2025:<\/h3><div><h4>Oral Abstract:<\/h4><ul><li><div data-block-id=\"block-ae496ae0-b916-4235-9605-6a5003c26603\">Long-Term Efficacy Results of Epicutaneous Immunotherapy With VIASKIN<sup>\u00ae<\/sup> Peanut Patch in Peanut-Allergic Children. Aged 4-11 Years in the Phase 3 PEOPLE Study: San Diego, CA &#8211; Fleischer DM, Ford LS, Oriel RC, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/03\/DBV2536046_AAAAI2025_PEOPLE-Y5_021725_V5_Final.pdf\" target=\"_blank\" rel=\"noopener\">Abstract<\/a>]<\/div><\/li><\/ul><\/div><section><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c48b5c2 elementor-widget elementor-widget-text-editor\" data-id=\"c48b5c2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>Eastern Food Allergy &amp; Comorbidity Conference, January 9-12, 2025<\/strong>:<\/h3><div><h4>Poster Presentations:<\/h4><ul><li>EPOPEX (EPITOPE Open-label Extension), Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers After 3 Years of Treatment: Palm Beach, FL \u2013 Greenhawt M, Wang J, Du Toit G, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/01\/DBV2433982_OLE-Y2_EFACC2025_010625_V3_Final.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><li>VP250 Average Daily Wear Time: Impact on Efficacy and Safety in the Phase 3 EPITOPE Study: Palm Beach, FL \u2013 Kim EH, Fleischer DM, Leonard S, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/01\/DBV2433982_Patch-Avg-Wear-Time-EPITOPE_EFACC2025_010725_V4_Final-For-Print.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><li>Changes in Biomarkers During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers: Palm Beach, FL \u2013 Kim EH, Lieberman J, Schneider L, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2025\/01\/DBV2433982_Biomarkers_EFACC2025_010725_V4_Final-for-Print.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/li><\/ul><\/div><section><\/section><section><\/section><section id=\"mk-footer-unfold-spacer\"><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d8c736a elementor-widget elementor-widget-text-editor\" data-id=\"d8c736a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>European Academy of Allergy and Clinical Immunology (EAACI) 2024 Annual Meeting, May 31-June 3, 2024:<\/h3><div id=\"text-block-24\" class=\"mk-text-block \"><h4>Presentation:<\/h4><ul><li><div class=\"ql-block\" data-block-id=\"block-ae496ae0-b916-4235-9605-6a5003c26603\">Reactions due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers: Valencia, Spain &#8211; Arends N, Vogelberg C, Turner PJ, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2024\/05\/DBV2427987_EAACI2024_APC_051324_V1_Final.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/div><\/li><\/ul><\/div><section id=\"mk-footer-unfold-spacer\"><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-784114f elementor-widget elementor-widget-text-editor\" data-id=\"784114f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>American Academy of Allergy, Asthma &amp; Immunology (AAAAI) 2024 Annual Meeting, February 23-26, 2024:<\/h3><div id=\"text-block-24\" class=\"mk-text-block \"><h4>Poster Presentation:<\/h4><ul><li><div class=\"ql-block\" data-block-id=\"block-ae496ae0-b916-4235-9605-6a5003c26603\">Long-Term Safety Results of Epicutaneous Immunotherapy (EPIT) With Viaskin Peanut in Peanut-Allergic Children Aged 4 Through 11 Years in the Phase 3 PEOPLE Study: Washington, DC \u2013 Fleischer DM, Ford LS, Sussman G, et al. [<a href=\"https:\/\/dbv-technologies.com\/wp-content\/uploads\/2024\/03\/DBV2325885_AAAAI2024_PEOPLE_021324_V8_For-Print.pdf\" target=\"_blank\" rel=\"noopener\">Poster<\/a>]<\/div><\/li><\/ul><\/div><section id=\"mk-footer-unfold-spacer\"><\/section>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-132fdf9 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"132fdf9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Ces publications scientifiques et pr\u00e9sentations sont propos\u00e9es \u00e0 des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de d\u00e9veloppement, et qui ne sont approuv\u00e9s pour commercialisation par aucune autorit\u00e9 r\u00e8glementaire ou de sant\u00e9 dans aucun pays du monde. Publications importantes Get the Quarterly Newsletter from DBV Technologies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9146,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-9152","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/pages\/9152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/comments?post=9152"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/pages\/9152\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/pages\/9146"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=9152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}